European Medicines Agency - Regulatory - Regulation of medicines

D - Description



  Description

Name

ReSViNET - Respiratory Syncytial Virus Network

Year of foundation 2014
Preterm and/or term newborn Yes
Infants from 1 month to less than 24 months of age Yes
Children from 2 years to less than 12 years of age Yes
Adolescents from 12 years to less than 18 years Yes
Paediatric age ranges of study participants covered by the network Preterm newborns - 18 years
Multispeciality? Specify No
Speciality/disease specific? Specify RSV Infectious disease only
Conditions covered? Specify Asthma, Wheeze, cystic fibrosis
Procedure/Intervention specific? Specify no
Number of collaborating countries 12
List of collaborating countries The United States, Brazil, Argentina, The United Kingdom, The Netherlands, Finland, France, Spain, Italy, Greece, South Africa, Australia
Number of collaborating centres 24
List of collaborating centres The University of Manchester, UMC Utrecht, QIMR Berghofer Medical Research Institute, Universita Degli Studi Di Torino, Australian Infectious Diseases Research Centre, St George's University Hospitals, Julius Clinical, The University of Queensland Australia, Monroe Carell Jr. Children's Hospital at Vanderbilt, Universita degli studi di Padova, King's College London, Turun Yliopistollinen keskussairaala turku university hospital, Respiratory & meningeal pathogens research unit, National and Kapodistrian University of Athens, The University of Edinburgh, Universidade de Santiago de Compostela, Infant Undacion para la Investigacion en Infectologia Infantil, University of Witwatersrand Johannesburg, Pontificia Universidade Catolica do Rio Grande Do Sul, CLEAR, Children's Health and Environment Program, WHO Collaborating Centre for Children's Health and Environment, Necker Enfants Malades Hospital Universitaire, Nationwide Children's
Type of activity/studies
Clinical Studies Yes
Experimental research Yes
Other activity Organising yearly Expert meetings